A depolymerase may be capable of degrading extracellular polymeric substances of Klebsiella pneumoniae capsular type K47. The depolymerase can degrade extracellular polymeric substances of Klebsiella pneumoniae. Such a depolymerase may be a) an enzyme having a sequence as set forth in SEQ ID NO: 1, or having at least 80% homology thereto and having an activity of degrading extracellular polymeric substances from K47 capsular Klebsiella pneumoniae; and/or b) an enzyme having a sequence as set forth in SEQ ID NO: 2, or having at least 80% homology thereto and having an activity of degrading extracellular polymeric substances from K47 capsular Klebsiella pneumoniae

The present invention relates to chimeric bacteriophage lysins which can be used to sanitize surfaces, for the treatment of bacterial infections and/or for the selective treatment of body odor-causing bacteria. The invention also includes synergistic combinations, methods of treatment and isolated polynucleotides which encode the chimeric lysins.

Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.

Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.

Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.

The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.

The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.

A purified phage having a specific bactericidal activity against Burkholderia pseudomallei (Bp), such as a Bp phage vB_BpP_HN01. A composition for preventing or treating an infectious disease caused by the Bp includes the phage as an active ingredient. The present disclosure further provides an antibiotic including the phage as an active ingredient, a feed additive composition including the phage as an active ingredient, and a disinfectant or a cleaning agent including the phage as an active ingredient. The present disclosure further provides a method for using the Bp. The purified phage has a specific bactericidal activity against the Bp. Therefore, the phage may be used for the prevention or treatment of an infectious disease caused by the Bp, and may also be widely used for the preparation of an antibiotic, a drug, a bactericide, an antiseptic, a disinfectant, and a diagnostic preparation for a bacterial infection.

Genetically modified phages are provided. Accordingly, there is provided a genetically modified phage comprising a polynucleotide encoding an anti-defense system polypeptide. Also provided are methods of producing and using same.

A depolymerase may be capable of degrading extracellular polymeric substances of Klebsiella pneumoniae capsular type K47. The depolymerase can degrade extracellular polymeric substances of Klebsiella pneumoniae. Such a depolymerase may be a) an enzyme having a sequence as set forth in SEQ ID NO: 1, or having at least 80% homology thereto and having an activity of degrading extracellular polymeric substances from K47 capsular Klebsiella pneumoniae; and/or b) an enzyme having a sequence as set forth in SEQ ID NO: 2, or having at least 80% homology thereto and having an activity of degrading extracellular polymeric substances from K47 capsular Klebsiella pneumoniae.